Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials

Expert Rev Vaccines. 2012 Jun;11(6):637-40. doi: 10.1586/erv.12.33.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / adverse effects*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Female
  • Humans
  • Male
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / toxicity*
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / adverse effects

Substances

  • Cancer Vaccines
  • Vaccines, Subunit
  • ERBB2 protein, human
  • Receptor, ErbB-2